α1 Antitrypsin deficiency: current best practice in testing and augmentation therapy.
about
Low serum levels of alpha1 anti-trypsin (α1-AT) and risk of airflow obstruction in non-primary α1-AT-deficient patients with compensated chronic liver diseaseInhaled alpha1-proteinase inhibitor therapy in patients with cystic fibrosis.Recent advances in understanding and treating COPD related to α1-antitrypsin deficiency.Cationic Nanoliposomes Meet mRNA: Efficient Delivery of Modified mRNA Using Hemocompatible and Stable Vectors for Therapeutic Applications.
P2860
α1 Antitrypsin deficiency: current best practice in testing and augmentation therapy.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
α1 Antitrypsin deficiency: current best practice in testing and augmentation therapy.
@ast
α1 Antitrypsin deficiency: current best practice in testing and augmentation therapy.
@en
α1 Antitrypsin deficiency: current best practice in testing and augmentation therapy.
@nl
type
label
α1 Antitrypsin deficiency: current best practice in testing and augmentation therapy.
@ast
α1 Antitrypsin deficiency: current best practice in testing and augmentation therapy.
@en
α1 Antitrypsin deficiency: current best practice in testing and augmentation therapy.
@nl
prefLabel
α1 Antitrypsin deficiency: current best practice in testing and augmentation therapy.
@ast
α1 Antitrypsin deficiency: current best practice in testing and augmentation therapy.
@en
α1 Antitrypsin deficiency: current best practice in testing and augmentation therapy.
@nl
P2860
P356
P1476
α1 Antitrypsin deficiency: current best practice in testing and augmentation therapy.
@en
P2093
Jorge Lascano
Michael A Campos
P2860
P304
P356
10.1177/1753465814542243
P577
2014-07-09T00:00:00Z